Disclosed positions
| TANGO THERAPEUTICS INC | TNGX | COM | $339,990,606 | 10,876,219 | SH | None |
| REVOLUTION MEDICINES INC | RVMD | COM | $93,640,000 | 500,000 | SH | None |
| ABIVAX SA | ABVX | SPONSORED ADS | $80,622,300 | 605,000 | SH | None |
| UNIQURE NV | QURE | SHS | $69,241,998 | 1,503,300 | SH | None |
| KODIAK SCIENCES INC | KOD | COM | $57,567,296 | 1,477,600 | SH | None |
| KYMERA THERAPEUTICS INC | KYMR | COM | $49,204,897 | 429,100 | SH | None |
| DEFINIUM THERAPEUTICS INC | DFTX | COM SHS | $46,969,440 | 998,500 | SH | None |
| REPLIMUNE GROUP INC | REPL | COM | $44,091,810 | 3,983,000 | SH | None |
| CELCUITY INC | CELC | COM | $43,577,368 | 416,530 | SH | None |
| Q32 BIO INC | QTTB | COM | $40,122,209 | 3,149,310 | SH | None |
| CAPRICOR THERAPEUTICS INC | CAPR | COM NEW | $33,595,356 | 1,395,156 | SH | None |
| PRECIGEN INC | PGEN | COM | $29,355,000 | 5,150,000 | SH | None |
| CORCEPT THERAPEUTICS INC | CORT | COM | $29,171,725 | 335,500 | SH | None |
| Surrozen Inc. | SRZN | COM NEW | $26,963,591 | 1,105,683 | SH | None |
| PROTAGONIST THERAPEUTICS INC | PTGX | COM | $20,838,600 | 170,000 | SH | None |
| VIR BIOTECHNOLOGY INC | VIR | COM | $19,014,540 | 1,866,000 | SH | None |
| VAXCYTE INC | PCVX | COM | $18,892,250 | 325,000 | SH | None |
| UROGEN PHARMA LTD | URGN | COM | $18,400,000 | 500,000 | SH | None |
| CORVUS PHARMACEUTICALS INC | CRVS | COM | $16,434,000 | 1,100,000 | SH | None |
| PTC THERAPEUTICS INC | PTCT | COM | $16,314,000 | 200,000 | SH | None |
| PRAXIS PRECISION MEDICINES I | PRAX | COM NEW | $15,553,339 | 46,457 | SH | None |
| AMYLYX PHARMACEUTICALS INC | AMLX | COM | $14,368,000 | 800,000 | SH | None |
| OCULAR THERAPEUTIX INC | OCUL | COM | $12,766,000 | 1,300,000 | SH | None |
| OPUS GENETICS INC | IRD | COM | $11,569,650 | 2,815,000 | SH | None |
| PALISADE BIO INC | PALI | COM | $10,031,739 | 4,799,875 | SH | None |
| APOGEE THERAPEUTICS INC | APGE | COM | $9,291,100 | 70,000 | SH | None |
| SPYRE THERAPEUTICS INC | SYRE | COM NEW | $8,878,000 | 100,000 | SH | None |
| COGENT BIOSCIENCES INC | COGT | COM | $8,707,500 | 225,000 | SH | None |
| CYTOKINETICS INC | CYTK | COM NEW | $8,519,000 | 100,000 | SH | None |
| RELAY THERAPEUTICS INC | RLAY | COM | $8,419,500 | 450,000 | SH | None |
| CRESCENT BIOPHARMA INC. | CBIO | COM | $8,166,348 | 453,686 | SH | None |
| CONTINEUM THERAPEUTICS INC | CTNM | CL A | $8,096,660 | 494,000 | SH | None |
| KAZIA THERAPEUTICS LTD | KZIA | SPONSORED ADS | $7,884,800 | 560,000 | SH | None |
| SHATTUCK LABS INC | STTK | COM | $6,940,000 | 1,000,000 | SH | None |
| AVALO THERAPEUTICS INC | AVTX | COM NEW | $6,930,000 | 375,000 | SH | None |
| FORTE BIOSCIENCES INC | FBRX | COM NEW | $5,833,125 | 274,500 | SH | None |
| RELMADA THERAPEUTICS INC | RLMD | COM | $5,827,374 | 842,106 | SH | None |
| MOONLAKE IMMUNOTHERAPEUTICS | MLTX | CLASS A ORD | $5,354,250 | 275,000 | SH | None |
| ZURA BIO LTD | ZURA | CLASS A ORD SHS | $5,310,000 | 900,000 | SH | None |
| CYBIN INC | HELP | COM NEW | $5,221,900 | 790,000 | SH | None |
| ODYSSEY THERAPEUTICS INC | ODTX | COMMON STOCK | $5,145,250 | 275,000 | SH | None |
| IMMATICS N.V | IMTX | SHS | $4,811,750 | 475,000 | SH | None |
| FAETH THERAPEUTICS inc | FTH | COM NEW | $4,512,625 | 180,505 | SH | None |
| STRUCTURE THERAPEUTICS INC | GPCR | SPONSORED ADS | $4,025,250 | 75,000 | SH | None |
| ORIC PHARMACEUTICALS INC | ORIC | COM | $3,790,500 | 350,000 | SH | None |
| AN2 THERAPEUTICS INC | ANTX | COM | $3,625,329 | 749,035 | SH | None |
| NEUMORA THERAPEUTICS INC. | NMRA | COM | $3,400,000 | 2,000,000 | SH | None |
| INOVIO PHARMACEUTICALS INC | INO | COM SHS | $3,129,493 | 2,844,994 | SH | None |
| ALLOGENE THERAPEUTICS INC | ALLO | COM | $3,120,000 | 1,500,000 | SH | None |
| SOLID BIOSCIENCES INC | SLDB | COM NEW | $2,997,000 | 300,000 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 1 positions lack a resolved ticker and 0 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.